Roche Pegasys Has 23% Market Share; Better Luck In Rematch With Intron?
Executive Summary
Roche's Pegasys has captured a 23% share of new prescriptions for hepatitis C in the U.S., Global Pharmaceutical Head William Burns told investors during a year-end conference in London Feb. 26
You may also be interested in...
Pegasys Catching Up To PEG-Intron; Schering Admits “Complacency”
Schering-Plough plans to focus more directly on maintaining market share in the pegylated interferon market after losing about one-third of its share to Roche, Global Pharmaceuticals President Carrie Cox told a July 23 conference call
Pegasys Catching Up To PEG-Intron; Schering Admits “Complacency”
Schering-Plough plans to focus more directly on maintaining market share in the pegylated interferon market after losing about one-third of its share to Roche, Global Pharmaceuticals President Carrie Cox told a July 23 conference call
Schering Global Pharma President Cox To Tackle Flagging Allergy Sales
The first priority for Schering-Plough's new Global Pharmaceutical President Carrie Cox will be implementing marketing changes for the company's allergy franchise